Product Center
Approved as Taizhou Engineering Research Center
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-07-03
- Views:
(Summary description)Recently, the Taizhou Municipal Development and Reform Commission announced the list of 2024 Taizhou Engineering Research Centers, and the "Taizhou Engineering Research Center for Human Vaccine Technology Innovation" established by Ab&B Bio-Tech Co. (hereinafter referred to as "Ab&B Bio") was successfully recognized as a Municipal Engineering Research Center.
Approved as Taizhou Engineering Research Center
(Summary description)Recently, the Taizhou Municipal Development and Reform Commission announced the list of 2024 Taizhou Engineering Research Centers, and the "Taizhou Engineering Research Center for Human Vaccine Technology Innovation" established by Ab&B Bio-Tech Co. (hereinafter referred to as "Ab&B Bio") was successfully recognized as a Municipal Engineering Research Center.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-07-03 17:05
- Views:
Recently, the Taizhou Municipal Development and Reform Commission announced the list of 2024 Taizhou Engineering Research Centers, and the "Taizhou Engineering Research Center for Human Vaccine Technology Innovation" established by Ab&B Bio-Tech Co. (hereinafter referred to as "Ab&B Bio") was successfully recognized as a Municipal Engineering Research Center.
It is understood that this recognition of the Taizhou Engineering Research Center aims to deeply practice the new development concept and innovation-driven development strategy, focusing on the development of new quality productivity in accordance with local conditions, accelerate the deep integration of the innovation chain, industrial chain, capital chain and talent chain, and promote the high-quality development of the city's strategic emerging industries.
Ab&B Bio will, through the continuous construction of the Taizhou Human Vaccine Technology Innovation Engineering Research Center, aim at solving the huge unmet demand for innovative human vaccines, combine this effort with the actual situation of the enterprise, further enhance the innovation level of the company's technology platform, continue to strengthen talent development and team building, carry out scientific and technological innovation and key core technology research, develop new-quality productive forces, and continuously promote the generation of original scientific and technological achievements. The company will continue to strengthen talent training and team building, carry out scientific and technological innovation and key core technology research, develop new productivity, continuously promote the output of original scientific and technological achievements, and contribute to the high-quality development of the biomedical industry and the protection of people's lives, health and social welfare.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
